ArticleEuropean journal of immunology2021
Enrichment of CCR6
Article in European journal of immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- High-Dimensional Immunophenotyping of Post-COVID-19 and Post-Influenza Patients Reveals Persistent and Specific Immune Signatures After Acute Respiratory Infection.Journal of medical virology · 2025Article
- Harnessing 2D and 3D human endometrial cell culture models to investigate SARS-CoV-2 infection in early pregnancy.Clinical science (London, England : 1979) · 2025Article
- Potential therapeutic targets for COVID-19 complicated with pulmonary hypertension: a bioinformatics and early validation study.Scientific reports · 2024Article
- Screening compounds for treating the diabetes and COVID-19 from Miao medicine by molecular docking and bioinformatics.Arabian journal of chemistry · 2023Article
- Constructing a full, multiple-layer interactome for SARS-CoV-2 in the context of lung disease: Linking the virus with human genes and microbes.PLoS computational biology · 2023Article
- Integrative multi-omics approach for identifying molecular signatures and pathways and deriving and validating molecular scores for COVID-19 severity and status.BMC genomics · 2023Article
- CCR6 as a Potential Target for Therapeutic Antibodies for the Treatment of Inflammatory Diseases.Antibodies (Basel, Switzerland) · 2023Review
- Innate and Adaptive Immunity during SARS-CoV-2 Infection: Biomolecular Cellular Markers and Mechanisms.Vaccines · 2023Review
- COVID-19 immunopathology: From acute diseases to chronic sequelae.Journal of medical virology · 2023Review
- Pathobiology and dysbiosis of the respiratory and intestinal microbiota in 14 months old Golden Syrian hamsters infected with SARS-CoV-2.PLoS pathogens · 2022Article
- Immune checkpoint alterations and their blockade in COVID-19 patients.Blood science (Baltimore, Md.) · 2022Review
- SARS-CoV-2-specific CD4iScience · 2022Article
- Heterogenous CD8+ T Cell Maturation and 'Polarization' in Acute and Convalescent COVID-19 Patients.Viruses · 2022Article
- SARS-CoV-2-reactive IFN-γ-producing CD4Scientific reports · 2022Article
- Human-host transcriptomic analysis reveals unique early innate immune responses in different sub-phenotypes of COVID-19.Clinical and translational medicine · 2022Article
- Article
- Frontline workers: Mediators of mucosal immunity in community acquired pneumonia and COVID-19.Frontiers in immunology · 2022Review
- Exploring SARS-CoV2 host-pathogen interactions and associated fungal infections cross-talk: Screening of targets and understanding pathogenesis.Computational and structural biotechnology journal · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Despite high levels of CXCR3 ligands in mechanically ventilated COVID-19 patients, BALF CD8 T cells were not enriched in CXCR3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.